cardiovascular disease
Biotech

Novo calls off $598M Heartseed collab, citing 'strategic reviews'

Japanese biotech Heartseed said it was "difficult to reasonably foresee" that Novo would scrap the 2021 deal, despite the pharma's restructuring.
Zoey Becker Sep 30, 2025 1:55pm
Anthony Letai

Dana-Farber oncologist Anthony Letai tapped to direct NCI

Sep 30, 2025 5:50am
Inside the small intestine

Fractyl delivers data on its device for GLP-1 weight maintenance

Sep 30, 2025 12:10pm
Olympus

Olympus launches AI for spotting polyps in colonoscopy

Sep 30, 2025 11:30am
workers

Fierce Biotech Layoff Tracker 2025: Heidelberg, IO & more

Sep 30, 2025 11:00am
Metallic arrow symbols which are illuminated by blue and magenta lights merge on blue and magenta b

Barinthus enters reverse merger with metabolic disease biotech

Sep 30, 2025 10:39am
More News

Anaptys plans to split into 2 businesses

Sep 30, 2025 9:35am

Opus sets sights on FDA talks after posting gene therapy data

Sep 30, 2025 9:15am

Fierce Biotech Fundraising Tracker: Crystalys, Star & more

Sep 30, 2025 8:30am

Novo Holdings-backed biotech raises $205M to fill gout care gap

Sep 30, 2025 8:00am